The European Medicines Agency insists the benefits of the Johnson and Johnson vaccine outweigh the risks of side effects.
Its rollout has been delayed in Europe as the company investigates rare blood clots in people who have received the vaccine in the US.
The EMA says it is investigating the six reported cases along with US regulators.
Advertisement
Next week the EMA will decide whether any regulatory action needs to be taken on the single-shot vaccine.
